Ilana Golub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ilana Golub has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Jay Budoff
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA
5 shared publications - April Kinninger
The Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
3 shared publications - Suraj Dahal
Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
3 shared publications - A. Cai
Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, 90502, USA
2 shared publications A. Onuegbu
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, United States
2 shared publications- Abhinav R. Thummala
David Geffen School of Medicine, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA
2 shared publications
Latest Publications
- 7 April 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (9) , 104036
The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial
- 7 April 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (9) , 104036
The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial
- Open Access
- 19 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2095
Artificial Intelligence in Nuclear Cardiac Imaging: Novel Advances, Emerging Techniques, and Recent Clinical Trials
Cardiovascular disease (CVD) is a leading cause of death, accounting for over 30% of annual global fatalities. Ischemic heart disease, in turn, is a frontrunner of worldwide CVD mortality. With the burden of coronary disease rapidly growing, understanding the nuances of cardiac imaging and risk prognostication becomes paramount. Myocardial perfusion imaging (MPI) is a frequently utilized and well established testing modality due to its significant clinical impact in disease diagnosis and risk assessment. Recently, nuclear cardiology has witnessed major advancements, driven by innovations in novel imaging technologies and improved understanding of cardiovascular pathophysiology. Applications of artificial intelligence (AI) to MPI have enhanced diagnostic accuracy, risk stratification, and therapeutic decision-making in patients with coronary artery disease (CAD). AI techniques such as machine learning (ML) and deep learning (DL) neural networks offer new interpretations of immense data fields, acquired through cardiovascular imaging modalities such as nuclear medicine (NM). Recently, AI algorithms have been employed to enhance image reconstruction, reduce noise, and assist in the interpretation of complex datasets. The rise of AI in nuclear medicine (AI-NM) has proven itself groundbreaking in the efficiency of image acquisition, post-processing time, diagnostic ability, consistency, and even in risk-stratification and outcome prognostication. To that end, this narrative review will explore these latest advances in AI in nuclear medicine and its rapid transformation of the cardiac diagnostics landscape. This paper will examine the evolution of AI-NM, review novel AI techniques and applications in nuclear cardiac imaging, summarize recent AI-NM clinical trials, and explore the technical and clinical challenges in its implementation of artificial intelligence.
- 19 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2095
Open AccessArtificial Intelligence in Nuclear Cardiac Imaging: Novel Advances, Emerging Techniques, and Recent Clinical Trials
Cardiovascular disease (CVD) is a leading cause of death, accounting for over 30% of annual global fatalities. Ischemic heart disease, in turn, is a frontrunner of worldwide CVD mortality. With the burden of coronary disease rapidly growing, understanding the nuances of cardiac imaging and risk prognostication becomes paramount. Myocardial perfusion imaging (MPI) is a frequently utilized and well established testing modality due to its significant clinical impact in disease diagnosis and risk assessment. Recently, nuclear cardiology has witnessed major advancements, driven by innovations in novel imaging technologies and improved understanding of cardiovascular pathophysiology. Applications of artificial intelligence (AI) to MPI have enhanced diagnostic accuracy, risk stratification, and therapeutic decision-making in patients with coronary artery disease (CAD). AI techniques such as machine learning (ML) and deep learning (DL) neural networks offer new interpretations of immense data fields, acquired through cardiovascular imaging modalities such as nuclear medicine (NM). Recently, AI algorithms have been employed to enhance image reconstruction, reduce noise, and assist in the interpretation of complex datasets. The rise of AI in nuclear medicine (AI-NM) has proven itself groundbreaking in the efficiency of image acquisition, post-processing time, diagnostic ability, consistency, and even in risk-stratification and outcome prognostication. To that end, this narrative review will explore these latest advances in AI in nuclear medicine and its rapid transformation of the cardiac diagnostics landscape. This paper will examine the evolution of AI-NM, review novel AI techniques and applications in nuclear cardiac imaging, summarize recent AI-NM clinical trials, and explore the technical and clinical challenges in its implementation of artificial intelligence.
- 1 June 2021
- Published by Elsevier in Atherosclerosis
- Vol. 326, 17-24
Utilizing coronary artery calcium to guide statin use
- 1 June 2021
- Published by Elsevier in Atherosclerosis
- Vol. 326, 17-24
Utilizing coronary artery calcium to guide statin use
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S38-S39
Lower Utilization Of Contrast Media And Beta-blocker In 256-detector Ge Revolution Ct Scanner: The Converge Registry
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S38-S39
Lower Utilization Of Contrast Media And Beta-blocker In 256-detector Ge Revolution Ct Scanner: The Converge Registry